# US 10,946,021 B2 · Methods of treating or alleviating joint diseases by administering an inhibitor of discoidin domain receptor 1 (DDR1) > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,946,021 B2 - Document ID: US10946021B2 - Status: Granted - Kind: B2 - Application number: 16/496,666 - Filed: 2018-03-23 - Published: 2020-01-30 - Granted: 2021-03-16 - Earliest claimed: 2017-03-23 - Assignees: Kaohsiung Medical University - Applicants: Kaohsiung Medical University - Inventors: Chau-Zen Wang; Chung-Hwan Chen; Liang-Yin Chou; Yu Chou; Mei-Ling Ho; Yi-Hsiung Lin - Web page: https://patentgrep.com/patent/US10946021B2 ## CPC - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 19/04: for non-specific disorders of the connective tissue - C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72} - C12N 15/1138: {against receptors or cell surface proteins} - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C12N 2310/11: Antisense - C12N 2310/14: interfering nucleic acids [NA] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to a use of Discoidin Domain Receptor 1 (DDR1) inhibitor in preparing a medicament for preventing or treating a joint disease. The present invention further relates to a use of DDR1 activator in preparing a medicament for preventing or treating abnormalities of endochondral ossification-related conditions. ## Claims ### Claim 1 A method for treating or alleviating a joint symptom associated with degenerative arthritis in a subject, comprising: identifying the subject having the degenerative arthritis; and administering to the subject an effective amount of a composition including a Discoidin Domain Receptor 1 (DDR1) inhibitor, wherein the DDR1 inhibitor is ### Claim 2 (depends on 1) The method as claimed in claim 1, wherein the joint symptom is a joint disease. ### Claim 3 (depends on 2) The method as claimed in claim 2, wherein the joint disease is a degenerative joint disease. ### Claim 4 (depends on 3) The method as claimed in claim 3, wherein the degenerative joint disease is osteoarthritis. ### Claim 5 (depends on 3) The method as claimed in claim 3, wherein the degenerative joint disease is caused by a joint injury, an anterior cruciate ligament injury, or aging. ### Claim 6 (depends on 5) The method as claimed in claim 5, wherein the joint injury is at least one of a traumatic injury and a post-operative injury. ### Claim 7 (depends on 1) The method as claimed in claim 1, wherein the subject is a human subject. ### Claim 8 (depends on 1) The method as claimed in claim 1, wherein the DDR1 inhibitor is ### Claim 9 (depends on 1) The method as claimed in claim 1, wherein the subject has a condition associated with increased levels of mammalian target of rapamycin (mTOR) and collagen type X. ### Claim 10 (depends on 9) The method as claimed in claim 9, wherein the condition associated with the increased levels of mTOR and collagen type X increases a potential development of at least one of a cartilage degradation and a chondrocyte death in the subject, and the administration of the composition inhibits, mitigates or alleviates the condition. ### Claim 11 A method for treating or alleviating a degenerative joint disease in a subject, comprising: administering to the subject an effective amount of a composition including a Discoidin Domain Receptor 1 (DDR1) inhibitor for treating or alleviating the degenerative joint disease in the subject, wherein the DDR1 inhibitor is ### Claim 12 (depends on 11) The method as claimed in claim 11, wherein the subject has an articular cartilage damage. ### Claim 13 (depends on 11) The method as claimed in claim 11, wherein the degenerative joint disease is osteoarthritis. ### Claim 14 A method for reducing, inhibiting, mitigating or alleviating at least one of a cartilage degradation and a chondrocyte death in a subject suffering therefrom, comprising: administering to the subject an effective amount of a Discoidin Domain Receptor 1 (DDR1) inhibitor, thereby reducing, inhibiting, mitigating or alleviating the at least one of the cartilage degradation and the chondrocyte death in the subject, wherein the DDR1 inhibitor is ### Claim 15 (depends on 14) The method as claimed in claim 14, wherein the subject has a traumatic injury to cartilage tissues. ### Claim 16 (depends on 14) The method as claimed in claim 14, wherein the DDR1 inhibitor specifically or preferentially inhibits DDR1 activity.